Ovarian Cancer: A Silent Killer's Devastating Return

Vanja Wilson's battle with stage four ovarian cancer, a disease colloquially known as the 'silent killer,' underscores a critical lack of progress in treatment. Diagnosed two years ago, her cancer spread aggressively, requiring extensive surgery and chemotherapy. Initially responding to a PARP inhibitor, Ms. Wilson depleted her superannuation when the drug wasn't subsidized.

Her recurrence illustrates the grim 90% rate for stage four ovarian cancer. Ms. Wilson's experience, along with those of Jemima Leydon (diagnosed at five) and Candice Hung (whose cancer returned after nine years), reveals that treatments have seen minimal change over decades.

This stagnation is attributed to decades of underfunding, leaving ovarian cancer with devastatingly low survival rates compared to other cancers. Patients like Ms. Wilson are left with limited options, often facing disbelief due to their healthy appearance despite advanced disease.

Advocates like Ms. Wilson and Ms. Leydon are calling for government attention and increased funding. They point to the significant advancements in breast and cervical cancer research as proof of what investment can achieve, emphasizing the urgent need to improve outcomes for women facing ovarian cancer.